KNSA
Kiniksa Pharmaceuticals, Ltd. NASDAQ$57.62
Mkt Cap $4.3B
52w Low $24.85
99.7% of range
52w High $57.72
50d MA $46.52
200d MA $40.40
P/E (TTM)
69.1x
EV/EBITDA
32.1x
P/B
7.2x
Debt/Equity
0.0x
ROE
12.1%
P/FCF
120.4x
RSI (14)
—
ATR (14)
—
Beta
0.06
50d MA
$46.52
200d MA
$40.40
Avg Volume
695.8K
About
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammato…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 0.18 | 0.27 | +50.0% | 53.85 | +0.1% | -1.6% | -0.1% | +2.6% | +7.0% | +7.0% | — |
| Feb 24, 2026 | TNS | 0.29 | 0.17 | -41.4% | 43.50 | +0.0% | -1.7% | -0.0% | +2.3% | +5.7% | +4.3% | — |
| Oct 28, 2025 | TNS | 0.33 | 0.23 | -30.3% | 39.43 | -0.4% | -5.2% | -5.4% | -6.1% | -5.0% | -2.3% | — |
| Jul 29, 2025 | TNS | 0.18 | 0.23 | +27.8% | 30.37 | +1.5% | -1.0% | -0.4% | +5.3% | +8.5% | +8.9% | — |
| Apr 29, 2025 | TNS | 0.02 | 0.11 | +450.0% | 25.88 | +0.5% | +4.2% | +7.2% | +6.8% | +7.3% | +4.1% | — |
| Feb 25, 2025 | TNS | -0.06 | -0.12 | -100.0% | 19.72 | +1.3% | -0.2% | -0.5% | +2.8% | +8.8% | +8.2% | — |
| Oct 29, 2024 | TNS | -0.02 | -0.18 | -662.4% | 23.27 | +0.1% | -1.1% | -2.9% | -3.4% | -7.7% | -5.3% | — |
| Jul 23, 2024 | TNS | -0.09 | -0.06 | +33.3% | 26.29 | -1.1% | -4.1% | -1.4% | -0.6% | -0.6% | +0.7% | — |
| Apr 23, 2024 | TNS | -0.14 | -0.25 | -78.6% | 17.68 | +3.0% | +1.0% | -0.4% | +1.1% | +4.9% | +5.9% | — |
| Feb 28, 2024 | TNS | -0.11 | 0.04 | +136.4% | 20.36 | +2.3% | +3.8% | +6.8% | -0.8% | -0.9% | +3.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $53.85 | $53.91 | +0.1% | -1.6% | -0.1% | +2.6% | — | — |
| Apr 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $53.85 | $53.91 | +0.1% | -1.6% | -0.1% | +2.6% | — | — |
| Apr 29 | Citigroup | Maintains | Buy → Buy | — | $53.85 | $53.91 | +0.1% | -1.6% | -0.1% | +2.6% | — | — |
| Apr 29 | Wedbush | Maintains | Outperform → Outperform | — | $53.85 | $53.91 | +0.1% | -1.6% | -0.1% | +2.6% | — | — |
| Apr 28 | Jefferies | Maintains | Buy → Buy | — | $43.61 | $47.20 | +8.2% | +23.5% | +21.5% | +23.3% | +26.7% | — |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $45.89 | $46.44 | +1.2% | -1.2% | -2.2% | -7.5% | -7.5% | -6.2% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $43.50 | $43.50 | +0.0% | -1.7% | -0.0% | +2.3% | +5.7% | +4.3% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $43.50 | $43.50 | +0.0% | -1.7% | -0.0% | +2.3% | +5.7% | +4.3% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $41.12 | $41.55 | +1.0% | -6.1% | -3.8% | -7.8% | -4.2% | -0.2% |
| Oct 29 | Goldman Sachs | Maintains | Buy → Buy | — | $39.43 | $39.29 | -0.4% | -5.2% | -5.4% | -6.1% | -5.0% | -2.3% |
Recent Filings
8-K
Kiniksa Pharmaceuticals International, plc Class A -- 8-K Filing
Kiniksa Pharmaceuticals reports strong Q1 2026 results with continued ARCALYST revenue growth in recurrent pericarditis, demonstrating successful market expansion five years post-launch of their IL-1 inhibitor therapy.
Apr 28
8-K
Kiniksa Pharmaceuticals International, plc Class A -- 8-K Filing
Kiniksa Pharmaceuticals reported 2025 financial results and portfolio progress, with management hosting a conference call to discuss fourth-quarter performance and commercial advancements in cardiovascular therapies.
Feb 24
Data updated apr 25, 2026 5:46pm
· Source: massive.com